Brief: Bone Therapeutics Says JTA Efficacy Results Are Disappointing

Biosenic SA

30/08/2021 06:16

Aug 30 (Reuters) - BONE THERAPEUTICS SA  BOTHE.BR :
    * NO STATISTICALLY SIGNIFICANT DIFFERENCE IN KNEE PAIN
REDUCTION
BETWEEN JTA-004, PLACEBO AND ACTIVE COMPARATOR, 3 MONTHS AFTER
TREATMENT; FAVOURABLE JTA SAFETY PROFILE SIMILAR TO PLACEBO AND
COMPARATOR
    * PRIME FOCUS ON CONTINUED DEVELOPMENT AND EXPANSION OF ITS
MESENCHYMAL STROMAL CELL-BASED ALLOGENEIC CELL AND GENE THERAPY
PLATFORM
    * COMPANY, IN COLLABORATION WITH EXISTING AND POTENTIAL
PARTNERS,
WILL CONSIDER OPTIONS FOR FUTURE OF JTA DEVELOPMENT
    * EXECUTION OF STUDY WAS FLAWLESS AND A GOOD SAFETY PROFILE
WAS
OBSERVED IN LINE WITH PREVIOUS RESULTS
    * THESE JTA EFFICACY RESULTS ARE DISAPPOINTING
    * WE ARE NOW FULLY COMMITTED TO CLINICAL DEVELOPMENT OF OUR
ADVANCED MSC ALLOGENEIC CELL AND GENE THERAPY PLATFORM
    * ALLOB: RECRUITMENT IS EXPECTED TO BE COMPLETED IN FIRST
HALF OF
2022 AND TOPLINE RESULTS BY END OF 2022
    * SHOULD PANDEMIC CONTINUE, BONE THERAPEUTICS MAY HAVE TO
RE-EVALUATE THESE TIMELINES

Source text for Eikon:  ID:nNDL1JpGhl 
Further company coverage:  BOTHE.BR 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))